Trial
NCT05605093
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
University of Minnesota
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Condition
COVID-19
Intervention
Shionogi Protease Inhibitor (S-217622)
Why stopped
DSMB closed due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-17